Structured evidence table for Glucosamine Osteoarthritis Systematic Review, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Glucosamine Osteoarthritis Systematic Review | Non-steroidal anti-inflammatory drugs (NSAIDs), as first-line pharmacological agents, provide symptomatic improvement but are associated with gastrointestinal bleeding and cardiovascular risks upon prolonged administration. | 1 | Shi Chuankai (2026) | Efficacy and safety of different curcumin formulations in osteoarthritis: an umbrella review of systematic reviews |
| Glucosamine Osteoarthritis Systematic Review | Systematic reviews and meta-analyses of observational studies indicate substantial heterogeneity in NSAID utilization among OA patients, with generally limited evidence quality (). | 1 | Shi Chuankai (2026) | Efficacy and safety of different curcumin formulations in osteoarthritis: an umbrella review of systematic reviews |
| Glucosamine Osteoarthritis Systematic Review | Emerging evidence has identified histone lactylation—a lactate-driven epigenetic modification—as a key player in OA progression, suggesting that targeting lactate metabolism or lactylation pathways may offer new therapeutic opportunities (). | 1 | Shi Chuankai (2026) | Efficacy and safety of different curcumin formulations in osteoarthritis: an umbrella review of systematic reviews |
| Glucosamine Osteoarthritis Systematic Review | 1 2 4 5 6 7 Osteoarthritis (OA) represents a leading global cause of joint pain and functional disability, substantially impairing patients’ quality of life (). | 1 | Shi Chuankai (2026) | Efficacy and safety of different curcumin formulations in osteoarthritis: an umbrella review of systematic reviews |
| Glucosamine Osteoarthritis Systematic Review | , , d d N Figure Chondroitin sulfate (CS) is an anionic, sulfated glycosaminoglycan found in various connective tissues, including cartilage, bone, ligaments, tendons, and skin. | 3 | Silva Vitor Alfredo de Santana (2025) | Impact of Symptomatic Slow-Acting Drugs on Inflammatory Pathways in Osteoarthritis: Therapeutic Advances and Future Challenges |
| Glucosamine Osteoarthritis Systematic Review | In terrestrial animals, it is predominantly found as monosulfated disaccharides at the 4-O or 6-O positions of GalNAc (CS-A and CS-C, respectively), along with a small percentage of nonsulfated disaccharides (CS-0). | 3 | Silva Vitor Alfredo de Santana (2025) | Impact of Symptomatic Slow-Acting Drugs on Inflammatory Pathways in Osteoarthritis: Therapeutic Advances and Future Challenges |
| Glucosamine Osteoarthritis Systematic Review | While foundational and pioneering studies are acknowledged, particular emphasis is placed on the most recent evidence to capture the current state of knowledge, clarify ongoing controversies, and highlight the latest therapeutic advances. | 3 | Silva Vitor Alfredo de Santana (2025) | Impact of Symptomatic Slow-Acting Drugs on Inflammatory Pathways in Osteoarthritis: Therapeutic Advances and Future Challenges |
| Glucosamine Osteoarthritis Systematic Review | Osteoarthritis (OA) is a highly prevalent musculoskeletal rheumatic disorder that significantly impacts individual health, healthcare systems, and overall socioeconomic costs.OA remains a substantial global health burden: in 2020, an estimated 595 million people (≈7.6% of the global population) had OA, representing a 132.2% increase in cases since 1990. | 3 | Silva Vitor Alfredo de Santana (2025) | Impact of Symptomatic Slow-Acting Drugs on Inflammatory Pathways in Osteoarthritis: Therapeutic Advances and Future Challenges |
Source documents